IN THE CLAIMS:

Please cancel claims 1-66 without prejudice or disclaimer.

Please add the following new claims:

--67. A chimeric antibody to human interleukin-6 receptor (IL-6R), comprising:

(1) light chains (L chains) each comprising a human L chain constant region (C region) and an L chain variable region (V region) of a mouse monoclonal antibody to human IL-6R; and

(2) heavy chains (H chains) each comprising a human H chain C region, and H chain V region of a mouse monoclonal antibody to human IL-6R;

wherein the mouse L chain V region includes an amino acid sequence shown in SEQ ID Nos: 24 or ~~26~~ 28 and the mouse H chain V region includes an amino acid sequence shown in SEQ ID Nos: ~~25~~ 26 or ~~27~~ 30.

68. The chimeric antibody according to claim 67, wherein the human L chain C region is a human Kc region.

69. The chimeric antibody according to claim 67, wherein the H chain C region is a human γ-1C region.

70. The chimeric antibody according to claim 68, wherein the H chain C region is a human γ-1C region.

71. An isolated DNA encoding an L chain comprising a human L chain C region and an L chain V region of a mouse monoclonal antibody to human IL-6R wherein the human L chain C region is a human Kc region and the L chain V region includes the amino acid sequence set forth in SEQ ID NOS: 24 or ~~26~~ 28.

72. An isolated DNA encoding an H chain comprising a human H chain C region and an H chain V region of a mouse monoclonal antibody to IL-6R, wherein the human H chain C region is a human γ-1C region and the H chain V region includes the amino acid sequence set forth in SEQ ID NOS: ~~25 or 27~~ 26 or 30.

73. An expression vector comprising a DNA coding for an L chain comprising a human L chain C region and L chain V region of a mouse monoclonal antibody to human IL-6R, wherein the human L chain C region is a human Kc region, and the L chain V region includes an amino acid sequence shown in SEQ ID NOS: 24 or ~~26~~ 28.

74. An expression vector comprising a DNA coding for an H chain comprising a human H chain C region and H chain V region of a mouse monoclonal antibody to human IL-6R, wherein the human L chain C region is a human Kc region, and the L chain V region includes an amino acid sequence shown in SEQ ID NOS: ~~25 or 27~~ 26 or 30.

75. A host cell co-transformed with:

(1) an expression vector comprising a DNA coding for an L chain comprising a human L chain C region and an L chain V region of a mouse monoclonal antibody to human IL-6R, and with

(2) an expression vector comprising a DNA coding for an H chain comprising a human H chain C region and an H chain V region of a mouse monoclonal antibody to IL-6R, wherein the human L chain C region is a human Kc region; the L chain V region includes an amino acid sequence shown in SEQ ID NOS: 24 or ~~26~~ 28, the human L chain C region is a human γ-1C region and the H chain V region includes an amino acid sequence shown in SEQ ID NOS: ~~25~~ 26 or ~~27~~ 30.

76. A method of producing the chimeric antibody to human IL-6R according to claim 67, said method at least comprising the steps of:

(a) culturing host cells co-transformed with a first expression vector and a second expression vector, for a time and under conditions sufficient for expression to occur, wherein the first expression vector comprises DNA encoding a human L chain C region and a mouse L chain V region including the sequence set forth in SEQ ID NOS: 24 or ~~26~~ 28 and the second expression vector comprises DNA encoding a human H chain C region and a mouse H chain V region including a sequence set forth in SEQ ID NOS: ~~25~~ 26 or ~~27~~ 30; and

(b) recovering the chimeric antibody from the culture.--

SEQUENCE LISTING

The Sequence Listing from the parent application has been added to the present specification by the above amendments. Applicant requests that the computer readable form of the Sequence Listing submitted in the parent application be used to satisfy the sequence listing requirement for the present application as well. The sequence information in the paper copy of the Sequence Listing submitted herewith is the same as the sequence information in the computer readable form submitted in the parent application. Therefore, applicants request that the computer readable form of the parent application be used to satisfy the sequence listing requirements for the instant application. No new matter has been introduced by the paper copy of the sequence listing, which is identical to that submitted in the parent application and which contains the same sequence information as the computer readable form in the parent application.